%0 Journal Article
%T A Randomized Controlled Trial of Two Schedules of Hepatitis B Vaccination in Predialysed Chronic Renal Failure Patients
%A Farokhlagha Ahmadi
%A Morteza Ramezani
%A Effat Razeghi
%A Neda Ranjbarnovin
%J Hepatitis Monthly
%D 2012
%I Kowsar Corporation
%X Background: Patients with chronic renal disease should be vaccinated as soon as dialysis is forestalled, and this could improve the seroconversion of hepatitis B vaccination.Objectives: In this study, we aimed to compare seroconversion and immune response rates using 4 doses of 40 ¦Ìg and 3 doses of 20 ¦Ìg Euvax B recombinant Hepatitis B surface Antigen (HBs Ag) vaccine administered to predialysis patients with chronic kidney disease (CKD).Patients and Methods: In an open, randomized clinical trial, we compared seroconversion rates in 51 predialysis patients with mild and moderate chronic renal failure who received either 4 doses of 40 ¦Ìg or 3 doses of 20 ¦Ìg of Euvax B recombinant hepatitis B vaccine administered at 0, 1, 2, 6 and 0, 1, 6 months, respectively.Results: Differences in seroconversion rates after 4 doses of 40 ¦Ìg (80.88%) compared to 3 doses of 20 ¦Ìg (92%) were not significant (P = 0.4124). The mean HBs antibody level after 4 doses of 40 ¦Ìg at 0, 1, 2, and 6 months (182.2 ¡À 286.7) was significantly higher than that after 3 doses of 40 ¦Ìg at 0,1, and 6 months (96.9 ¡À 192.1) (P = 0.004). Seroconversion after 4 doses of 40 ¦Ìg (80.8%) was also significantly higher than that after 3 doses of 40 ¦Ìg (77%) (P = 0.004). Multivariable analysis showed that none of the variables contributed to seroconversion.Conclusions: We found that 4 doses of 40 ¦Ìg did not lead to significantly more seroconversion than 3 doses of 20 ¦Ìg.
%K Kidney Failure
%K Chronic
%K Hepatitis B
%K Vaccination
%U http://hepatmon.com/?page=article&article_id=6438